In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
about
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics.Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activitySynthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activityMicroneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticlesA nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activityPrevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model.Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticlesEnhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer.PEG Grafted-Nanodiamonds for the Delivery of Gemcitabine.Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.The in vitro and in vivo anti-tumor effects of MTX-Fe3O 4-PLLA-PEG-PLLA microspheres prepared by suspension-enhanced dispersion by supercritical CO2.An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure.Lipid-Drug Conjugate for Enhancing Drug Delivery.Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy.Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models.Pancreatic Cancer Chemoresistance to Gemcitabine.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
P2860
Q34149180-CAA91D00-8549-43DE-A5F2-B14EE05404B9Q35610203-D1CC1316-8CED-41A2-9A6F-9596C26DD5E5Q35659449-5CE4581F-71E6-483F-8164-D68E62DD70CAQ35909171-D4A6548B-2907-4364-B6C0-60270FB8CB2BQ36164785-3606DC1C-0671-46BF-A361-73CB14EC8358Q36339297-52D7866A-7CA5-4408-9BFE-50BD6A25A70FQ36515306-F4F3EC20-1DAB-4567-A83A-4E5C03914CC5Q36521096-42EA1A61-089F-47C1-83B7-5060367497DEQ36553206-C09E2171-7412-4580-9012-F2561CCB2332Q36887757-D5FC6190-33AB-40F0-908E-E04E0CA18A66Q36931187-0747C5CF-762F-4B2B-9F28-E1B28C51A8A1Q37065888-E1487672-CB4F-4F95-A4AE-8208BF7BE36AQ37120657-09F974A5-1105-42C8-912B-A1C1AED83AD9Q37194819-139B8D24-BBE8-49B0-A77C-6DACCB911C3BQ37449234-A0AC3D51-A6C3-458E-B825-9AAC07843CA8Q37624646-03F9D73A-25E2-41BF-AC9C-BD58FB1925B9Q37714232-D9CD93B5-498D-406E-8977-A4759FC7D3B1Q37714256-496CF7B7-7CD0-4B0B-AAE8-0E72AF7EEA5CQ37994505-0E389EBD-7A78-43A7-AB54-AED622F65462Q38014497-273F27D0-507A-44E3-BB88-64B9020EE5A7Q38733010-34211F22-DFD2-4FEA-B301-14E909582E41Q38750556-FF62DDD8-E514-4B24-B503-72815FF57580Q38799790-6621A5B9-9596-4C4B-87D6-FD75EF7E2F59Q38984024-B9B8272D-3B92-46CD-A0CF-4900BD27BF41Q39013388-076F408A-50B8-46D2-9A20-829C0433B2B6Q39083391-044FBA4A-0017-45EB-B6E9-FAFCB1E96C90Q39249056-25CEE572-8DFC-4BE4-98D0-4B3776738ABDQ41860499-4BBC54DA-7C2C-4B13-9C24-1FA54D52B719Q45729918-4E857FDB-C7E5-4E5F-AF84-807DA4BE0256Q47135556-311AA922-D4BF-4DB2-836D-63266386725AQ49387560-2339CAC3-8EB0-4E3D-AF21-2D308A467827
P2860
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@ast
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@en
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@nl
type
label
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@ast
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@en
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@nl
prefLabel
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@ast
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@en
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@nl
P2093
P2860
P1476
In vitro and in vivo anti-tumo ...... tive carried by nanoparticles.
@en
P2093
Brian R Sloat
Dharmika S P Lansakara-P
John DiGiovanni
Kaoru Kiguchi
Michael A Sandoval
Philip J Proteau
Woon-Gye Chung
Zhengrong Cui
P2860
P304
P356
10.1016/J.IJPHARM.2011.02.037
P407
P577
2011-03-01T00:00:00Z